NIGHT HYPOTENSION/INTRAOCULAR PRESSURE ON CEREBRAL OCULAR BLOOD FLOW IN GLAUCOMA

本研究将评估非选择性β受体阻滞剂噻莫洛尔与具有内在拟交感神经活性（ISA）的β受体阻滞剂卡替洛尔对夜间血压、夜间心输出量、夜间眼压（IOP）和视觉功能变化的影响。最近的证据表明，高比例的原发性开角型青光眼（POAG）患者在血压和IOP方面都有不寻常的变化。局部β拮抗剂是降低POAG患者眼压的首选药物。虽然这些药物的全身性副作用是众所周知的，如降低心率、血压等，但它们通常被忽视，因为全身性心血管因素在疾病的发病机制中并不重要。然而，如果不同的-受体阻滞剂药物对心血管因素的作用有很大的不同，从而影响疾病的进展，那么选择治疗方案必须包括对每种药物的全身副作用进行更严格的审查。

The present study will evaluate the effects of a nonselective beta-blocking agent, timolol, versus a beta-blocker with intrinsic sympathomimetic activity (ISA), carteolol, on the variation of nocturnal blood pressure, nocturnal cardiac output, nocturnal intraocular pressure (IOP) and visual function. Recent evidence has shown that a high percentage of primary open angle glaucoma (POAG) patients have unusual variations in both blood pressure and IOP. Topical beta antagonist agents are the drugs of first choice for lowering IOP in POAG patients. Although the systemic side effects of these agents are well established, ie reduction in heart rate, blood pressure, etc, they have been generally ignored because systemic cardiovascular factors have not been considered important for the pathogenesis of the disease. However, if various beta-blocker drugs have substantially different effects on cardiovascular factors which in turn influence the progression of the disease, selection of a treatment regiment must include a more critical review of each drug's systemic side effects.